India's drug regulator has flagged a batch of the Abhayrab rabies vaccine as substandard and potentially spurious after it failed a potency test, raising concerns about counterfeit doses in the market.

IN · 2026-09-05

1. Step 1 · The triggerthe Central Drugs Laboratory flags a batch of the Abhayrab rabies vaccine as substandard after failing potency tests
2. Step 2 · Knock-onconcerns about counterfeit vaccines arise, prompting regulatory scrutiny on manufacturers
3. Step 3 · Knock-onWithheld This step of the chain is withheld. The reason is set out in the notice above — a deliberate omission, not missing data.
4. Step 4 · Knock-onincreased regulatory actions may lead to stricter compliance requirements for vaccine manufacturers and suppliers
5. Step 5 · Reaches youSMEs in the pharmaceutical sector must adapt to new regulations and potential shifts in market dynamics

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: The Hindu BusinessLine

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.